Search results
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Pharmaceutical Technology via Yahoo Finance· 6 days agoLast week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 15 hours ago(NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for < ...
EyePoint Pharmaceuticals’ stock plunges as eye treatment fails to meet trial goal
Market Watch· 1 day agodropped nearly 30% in premarket trading Monday after the company said its experimental...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga via Yahoo Finance· 1 day agoOn Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 5 days agoThree at-home vision-monitoring tools failed to detect worsening neovascular age-related macular ...
EyePoint tumbles 30% premarket on failed Phase 2 study (NASDAQ:EYPT)
Seeking Alpha· 1 day agoEyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase...
EyePoint Pharmaceuticals stock target cut, retains Buy rating By Investing.com
Investing.com· 4 hours agoTuesday, Mizuho adjusted its outlook on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), slashing the...
Analyst Report: Regeneron Pharmaceuticals, Inc.
Morningstar Research via Yahoo Finance· 2 days agoRegeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products ...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 - Ocular...
Benzinga· 6 days agoTherapeutix, Inc. OCUL "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative ...
EyePoint reports mixed results in diabetic retinopathy trial By Investing.com
Investing.com· 21 hours agoEyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) announced interim results from its Phase 2...